Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

Slides:

Advertisements

Similar presentations

Prevention of Ventilator Associated Pneumonia

Advertisements

ARE CAP AND HCAP TWO SEPARATE ENTITIES? Francesco Blasi Department Pathophysiology and Transplantation, University of Milan, Italy.

H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.

TREATMENT OF PNEUMONIA IN ADVANCED DEMENTIA Sophie Allepaerts CHU- Liège Belgium.

Ventilator-Associated Pneumonia. Introduction Definition 48 hours after intubation mechanically ventilated No clinical evidence of pneumonia prior to.

The Importance of Clinical Oral Care

Enoch Omonge University of Nairobi

H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.

Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.

Community Acquired Pneumonia (CAP)

Hospital-Acquired Pneumonia

Community Acquired Pneumonia. Definitions Community acquired pneumonia (CAP) – Infection of the lung parenchyma in a person who is not hospitalized or.

HAP and VAP Guidelines Update

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Figure 1. Rate of antimicrobial resistance in S. pneumoniae

Evaluation of susceptibility patterns of Pseudomonas aeruginosa in respiratory vs. non-respiratory infections and implications for empiric treatment Stephanie.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Clinical Microbiology and Infection

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Core, Magnet, Organ Donation

From: Rotarix: A Rotavirus Vaccine for the World

Figure 1. Paradigm for evaluation of those with latent tuberculosis infection (LTBI) based on risk of infection, risk of progression to tuberculosis, and.

Table 1 Criteria for proven invasive fungal disease except for endemic mycoses. From: Revised Definitions of Invasive Fungal Disease from the European.

Table 1 Characteristics of study population, by pneumococcal vaccination status. From: Prior Pneumococcal Vaccination Is Associated with Reduced Death,

From: Postinfectious Irritable Bowel Syndrome

Table 5 Sample format for results of Streptococcus pneumoniae isolate testing in a laboratory that routinely performs only oxacillin disk tests for penicillin.

Ventilator-Associated Tracheobronchitis

Figure 1 Annual per-capita consumption of all fermented milks and yogurt only in selected countries in Europe and North America [3, 4]. From: Probiotic.

Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation.

Clinical Microbiology and Infection

Antibiotic Resistance in Nosocomial Respiratory Infections

Intermountain APIC Chapter CIC training questions

Therapy of acute gastroenteritis: role of antibiotics

Antimicrobial Therapy for Life-threatening Infections: Speed is Life

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation Nicholas J. Gross, MD,

J. Rello, E. Afonso, T. Lisboa, M. Ricart, B. Balsera, A. Rovira, J

Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

Targeted antibiotic management of ventilator-associated pneumonia

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Paul E. Klapper, Graham M. Cleator Clinical.

G. Höffken Clinical Microbiology and Infection

Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands

Imaging for the Management of Community-Acquired Pneumonia

Ventilator-associated pneumonia—Understanding epidemiology and pathogenesis to guide prevention and empiric therapy Patrick Francioli, Jean Chastre,

Levofloxacin in the treatment of ventilator-associated pneumonia

J. Bodilsen, C. T. Brandt, A. Sharew, M. Dalager-Pedersen, T

Advisory group on Home-based and Outpatient Care (AdHOC): an international consensus statement on non-inpatient parenteral therapy D. Nathwani, J.-J.

Community-acquired pneumonia in adults

Community-acquired pneumonia: epidemiologic and clinical consideration

G.M. Rossolini, E. Mantengoli Clinical Microbiology and Infection

Figure 1. CONSORT flow diagram

W. Eugene Sanders, Christine C. Sanders

Infection services in the intensive care unit

Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia U. Hohenthal, S. Hurme, H. Helenius,

The atypical pneumonias: clinical diagnosis and importance

Medication Adherence: WHO Cares?

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Q Fever: Epidemiology, Diagnosis, and Treatment

Sahil Khanna, MBBS, MS, Pritish K. Tosh, MD Mayo Clinic Proceedings

Joshua P. Metlay, Daniel E. Singer Clinical Microbiology and Infection

Duration of antibiotic therapy according to clinical pulmonary infection score in a randomised trial of an antibiotic discontinuation policy for clinically.

Community Acquired Pneumonia

J. Segreti Clinical Microbiology and Infection

Compliance with empiric therapy guidelines for treatment of each type of pneumonia. Compliance with empiric therapy guidelines for treatment of each type.

Presentation transcript:

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted with permission of the American Thoracic Society [4]. Copyright © 1996 American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement. Am J Respir Crit Care Med 1996; 153:1711–1725. From: Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia Clin Infect Dis. 2010;51(Supplement_1):S48-S53. doi:10.1086/653049 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

Figure 2. Algorithm for initiating empirical antibiotic therapy for hospital- acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and health care-associated pneumonia (HCAP), according to the 2005 American Thoracic Society and Infectious Diseases Society of America guideline. *Prior antimicrobial therapy (within 90 days), hospitalization for ⩾5 days, high frequency of antibiotic resistance in the community or the hospital unit, immunosuppressive disease or therapy. Adapted with permission of the American Thoracic Society [5]. Copyright © 2005 American Thoracic Society. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated Pneumonia.Am J Respir Crit Care Med 2005; 171:388–416. From: Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia Clin Infect Dis. 2010;51(Supplement_1):S48-S53. doi:10.1086/653049 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

Table 1. Potential Microorganisms in Each Group According to the 1996 Consensus Statement of the American Thoracic Society From: Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia Clin Infect Dis. 2010;51(Supplement_1):S48-S53. doi:10.1086/653049 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

Table 2. Initial Empirical Antimicrobial Treatment for Patients with Hospital-Acquired, Ventilator-Associated, or Health Care-Associated Pneumonia, according to the 2005 American Thoracic Society and Infectious Disease Society of America Guidelines From: Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia Clin Infect Dis. 2010;51(Supplement_1):S48-S53. doi:10.1086/653049 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

Table 3. Numbers and Percentages of Microorganisms Responsible for 135 Episodes of Ventilator-Associated Pneumonia Classified According to the Duration of Mechanical Ventilation (MV) and Prior Antibiotic Therapy (ATB) From: Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia Clin Infect Dis. 2010;51(Supplement_1):S48-S53. doi:10.1086/653049 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America